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iomarkers in Heart Failure
oes Prognostic Utility
ranslate to Clinical Futility?*
lan Maisel, MD, FACC
an Diego, California
ardiac biomarkers are tools that should aid the physician
n one or more of the following: diagnosis and subsequent
isk stratification, risk stratification for secondary preven-
ion, guiding selection of therapy, and, finally, in some
ases, serving as a target for therapy. Since the advent of the
uccessful rapid uptake of natriuretic peptide levels for use in
eart failure, there have been a flurry of new biomarkers,
ost of which are being touted as prognostically important
n heart failure. Growth differentiating factor (GDF)-15 is
he latest marker that shows promise in this area. Growth
ifferentiating factor 15 has a number of overlapping path-
ays in the heart that make it a good choice for evaluation.
hile not normally expressed on cardiac myoctyes,
DF-15 does appear to be up-regulated in response to
xperimental pressure overload in the mouse model of
ardiomyopathy (1). In gene-targeted mice, GDF-15 has
itigating effects on hypertrophy, apoptosis, and remodel-
ng (2). In the present study, which included a cohort of 455
atients with congestive heart failure (CHF), GDF-15
emained an independent predictor of mortality, with addi-
ive value to New York Heart Association functional class,
jection fraction, and amino-terminal pro–B-type natri-
retic peptide (BNP) levels.
See page 1054
Although this study was well conceived, one must ask the
uestion whether a marker that provides independent prog-
ostic information beyond established clinical and biochem-
cal parameters automatically places it in the queue as the
next great biomarker” for CHF. To rise to the top means
utperforming the only currently accepted biomarker family
or heart failure, the natriuretic peptides. Although there are
any caveats concerning the use of natriuretic peptides in
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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harmaceuticals and is a consultant for Biosite, Inc.eart failure, at this time they are clearly the king of the
astle, a measure by which every other pretender or con-
ender will have to be compared.
hat Makes Natriuretic Peptide Levels
he Standard Bearers for Heart Failure Markers?
irst and foremost, a useful biomarker for CHF should have
lear pathophysiological relevance to the onset and progres-
ion of the disease. They should be used not only to help
iagnose the underlying condition or exacerbation of the
ondition, but the markers should be able to be manipulated
y treatment. More than that though is that its prognostic
apabilities should lend themselves to clinical decision-
aking. The only markers that approach this bar thus far
re the natriuretic peptides. Indeed, natriuretic peptides
both BNP and NT-proBNP) are excellent adjuncts for
uling in and ruling out heart failure in the setting of acute
yspnea (3,4). Their pathophysiology is so directly related to
he results of increased stress on the myocyte that exogenous
dministration of BNP (nesiritide) is effective treatment for
ecompensated CHF (5). But the notion that prognostic
mportance of natriuretic peptides is evolving into clinical
ools for decision-making is not only exciting but helps
hart the pathway for new players in the field. There are a
umber of areas where one is beginning to translate the
rognostic utility of natriuretic peptides into clinical utility.
cute Setting
n patients presenting to an emergency department with
yspnea, natriuretic peptide levels clearly aid in the diagno-
is of heart failure. The REDHOT (Rapid Emergency
epartment Heart Failure Outpatient Trial) study sug-
ested that the BNP level in patients presenting with
yspnea was much more important prognostically than any
ther feature, including the perceived severity of heart
ailure by the attending physicians (who were only told that
he BNP level was 100 pg/ml) (6). Extrapolating results
rom REDHOT suggests that patients’ presenting with
HF whose BNP level is 200 pg/ml may not gain any
dvantage by admission unless an associated comorbidity
ike pneumonia of acute coronary syndrome is present. The
act that 11% of patients were admitted with BNP levels
200 pg/ml in this study suggests that in a country where
5% to 90% of heart failure in the emergency room is
dmitted, millions of dollars in cost savings could be made
imply by discharging patients from the emergency depart-
ent with low BNP levels after appropriate treatment;
EDHOT also suggested that patients with BNP levels
bove 600 pg/ml might do better with admission but this
ust be substantiated by larger studies.
ospitalized Patients With Acute
ecompensated Congestive Heart Failure (ADHF)
hile there are many standard biomarkers that are prog-
ostic in the patient admitted with ADHF (blood urea
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Editorial Comment September 11, 2007:1061–3itrogen, creatinine, and uric acid, to name a few), natri-
retic peptides bring unique qualities to the hospitalized
etting. B-type natriuretic peptide, for instance, has a “wet”
nd “dry” component, “wet,” which correlates to the amount
f volume overload in the patient. As the half-life of BNP
s only 20 min, decongesting the patient will lead to a fall
n BNP levels of 50 to 75 pg/ml/h (7). Recently, this “wet”
NP level has been found to consist of “altered forms”
f BNP; these may include both the precursor, proBNP, as
ell as smaller fragments, which, while measured by current
atriuretic peptide assays, do not activate the natriuretic
eptide receptors, thus being termed “junk BNP” (8,9).
uture work may make it possible to have specific assays for
oth the “dry” and the wet” BNP.
Whereas BNP levels in the emergency department may
ictate admission, level of care, and type of treatment, the
ack of fall in BNP levels with treatment (especially early on)
s a poor prognostic sign that may signal additional mea-
ures may be necessary (10,11). In my own practice, patients
dmitted for ADHF receive initial parenteral diuretic ther-
py. But after 1 to 2 doses, if there is worsening of renal
unction, an inadequate urine output, and either no change
r an increase in BNP levels, patients are often begun on
ggressive vasodilator therapy with a drug like nesiritide.
Because declining BNP levels in the hospital can help
elineate a patients “optivolemic” volume status, it makes
ense that the lower the natriuretic peptide level is at
ischarge the better off the patient will be. Would we
acrifice an extra day or more hospitalization, ensuring the
NP level was at optivolemic status, if this would cut down
he 30-day readmission rate? The answer is likely to be yes,
et this data is currently lacking at the present time.
evertheless, the prognostic importance of natriuretic pep-
ide levels in the hospitalized patients with ADHF should
ead to better treatment algorithms in hopes of reducing
ospital readmission.
mbulatory CHF Patients
n the ambulatory setting, we have less information than we
ould like on how a prognostically important biomarker
ike BNP or troponin would influence outpatient therapy of
eart failure. In patients who appear at clinic in a decom-
ensated state, BNP levels are almost always increased.
hereas the individual variation of BNP levels may be
igh, McDonald’s group (12) recently found that a 56%
ncrease in values went along with decompensation.
Although drugs like angiotensin receptor blockers are
ssociated with an improved prognosis in patients with
HF along with decreasing natriuretic peptide levels (13),
he cause and effect has not been fully elucidated. Several
tudies have suggested that outpatient titration of drugs by
he BNP level leads to improved prognosis (14,15). How-
ver, this is still a slippery slope, as evidenced-based utili-
ation of life-saving medicines should still be given as per
uideline recommendation. tWhat about using prognostic biomarkers to help risk-
tratify patients for cardiac resynchronization therapy
CRT) and/or implantable cardioverter-defibrillator (ICD)
nsertion? The fact that up to one-third of patients who
eceive CRT are nonresponders behooves us to look closely
t other criteria for placement of these devices. While
tudies are few with small numbers of patients, the data thus
ar suggest the following:
Elevated BNP levels predict sudden death and ICD
firing (16,17).
Elevated preimplant BNP levels may identify CRT
responders, although those with lower BNP after implant
have better outcomes (18,19).
In CRT responders, BNP levels fall (20).
t present, BNP is not part of guidelines for ICD or CRT
mplantation. Certainly more work should be done in this
rea.
imitations of Natriuretic Peptide Testing
lthough natriuretic peptide testing is certainly part of
veryday practice, there are clear limitations to its useful-
ess. In the emergency department, grey zone numbers (100
o 400 pg/ml) need clinical correlation. Caveats such as
besity and renal dysfunction need to be accounted for. For
creening, it is still unclear as to what levels will provide
dded sensitivity or specificity to traditional testing (21).
he Future: GDF-15 and Beyond
ost of the currently used biomarkers were developed from
tudies of known proteins. Although this approach led to
ignificant advances, advances in protein display and iden-
ification technologies permit characterization of global
lterations associated with various disease states. Thus, the
eld of proteinomics is emerging as a novel approach for
iscovering biomarkers that directly relate to the patho-
hysiology of disease. These diseases processes are under-
tood to be related to changes in protein expression or
odification. Therefore, accurate detection of these alter-
tions in disease states by proteomics might enable us to
dentify potential drug targets, as well as biomarkers to
onitor disease progression or modification. The next steps
or GDF-15 is to further define cutoff values, assess how the
arker tracks with changes in treatment and clinical status,
nd, finally, to see if it can be an aid in clinical decision-
aking.
In conclusion, the study by Kempf et al. (22) in this issue
f the Journal demonstrates a promising new biomarker in
he prognosis of patients with heart failure. Further study
ill be needed to show whether this prognostic utility will
ranslate into clinical utility or futility.
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